Singapore markets open in 6 hours 35 minutes

Johnson & Johnson (JNJ)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
155.93+3.58 (+2.35%)
As of 02:25PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close152.35
Open152.76
Bid156.10 x 900
Ask156.12 x 800
Day's range152.33 - 156.16
52-week range143.13 - 175.97
Volume3,556,591
Avg. volume7,234,032
Market cap375.274B
Beta (5Y monthly)0.52
PE ratio (TTM)23.84
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield4.96 (3.26%)
Ex-dividend date27 Aug 2024
1y target estN/A
  • PR Newswire

    Johnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine) as the first and only monotherapy for adults with treatment-resistant depression

    Johnson & Johnson (NYSE: JNJ) announced today the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval of SPRAVATO® (esketamine) CIII nasal spray as a monotherapy for adults living with treatment-resistant depression (TRD). Nearly 30 percent of the estimated 280 million people worldwide living with major depressive disorder (MDD) have TRD,1 which occurs when there is an inadequate response to two or more oral antidepressants dur

  • Business Wire

    Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2024

    NEW BRUNSWICK, N.J., July 17, 2024--Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2024 of $1.24 per share on the company’s common stock. The dividend is payable on September 10, 2024 to shareholders of record at the close of business on August 27, 2024. The ex-dividend date is August 27, 2024.

  • Business Wire

    Johnson & Johnson reports Q2 2024 results

    NEW BRUNSWICK, N.J., July 17, 2024--Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2024. "Johnson & Johnson's second quarter performance reflects our relentless focus on advancing the next wave of medical innovation and resulted in strong sales and adjusted operational earnings per share growth," said Joaquin Duato, Chairman and Chief Executive Officer. "With a robust pipeline, upcoming regulatory milestones for RYBREVANT and TREMFYA, the integration of Shockwave, and c